<SEC-DOCUMENT>0001193125-15-216518.txt : 20150608
<SEC-HEADER>0001193125-15-216518.hdr.sgml : 20150608
<ACCEPTANCE-DATETIME>20150608170905
ACCESSION NUMBER:		0001193125-15-216518
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150604
FILED AS OF DATE:		20150608
DATE AS OF CHANGE:		20150608

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		15919061

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d937841d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated June 4, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 7, 151 Macquarie Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;</FONT><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): Not applicable. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June 4, 2015 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Prima BioMed Ltd</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PRIMA BIOMED TO MAINTAIN NASDAQ LISTING</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d937841dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937841g21r27.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4&nbsp;June 2015 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED TO MAINTAIN
NASDAQ LISTING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA&#151;Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR) (&#147;Prima&#148;, the &#147;Company&#148;), announces that, further
to the announcement made on 29&nbsp;December 2014, it has received a notice, dated 3&nbsp;June 2015 from the Listing Qualifications Department of The NASDAQ Stock Market indicating that, for the 10 consecutive business days from 19&nbsp;May 2015 to
2&nbsp;June 2015, the closing bid price of the Company&#146;s American Depositary Shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1) (&#147;the Minimum Bid Price Rule&#148;)
and the Company&#146;s shares will remain listed on The NASDAQ Global Market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prima BioMed </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment
of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s original product, called CVac, is an <I>ex vivo</I> dendritic cell priming therapy that in May 2015 yielded favourable Phase&nbsp;II data in
second remission ovarian cancer patients. Prima is currently seeking partners for further development of this therapy. Prima&#146;s current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the
regulation of the T&nbsp;cell immune response. IMP321, which is soluble LAG-3, is a T&nbsp;cell immunostimulatory factor for cancer chemoimmunotherapy which has completed early Phase&nbsp;II trials. A number of additional LAG-3 products including
antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is listed on the
Australian stock exchange and on the NASDAQ in the US. For further information please visit <U>www.primabiomed.com.au</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information
please contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prima BioMed Ltd: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stuart
Roberts, Global Head of Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;447 247 909; <U>stuart.roberts@primabiomed.com.au</U> </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>,
Level 7, 151 Macquarie Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 9276 1224&nbsp;&nbsp;&nbsp;&nbsp; Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>USA Investor/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adam Holdsworth, ProActive Capital </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646)&nbsp;862 4607;
adamh@proactivecapital.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia Investor/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski, Citadel Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;422
534 755; mgregorowski@citadelpr.com.au </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Europe Investor/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Axel M&uuml;hlhaus, edicto GmbH </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+49 (0)&nbsp;69
905505-52; amuehlhaus@edicto.de </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>,
Level 7, 151 Macquarie Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 9276 1224&nbsp;&nbsp;&nbsp;&nbsp; Fax: +61 2 9276 1284 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g937841g21r27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937841g21r27.jpg
M_]C_X``02D9)1@`!`0$`E@"6``#_X0!:17AI9@``24DJ``@````%``$#!0`!
M````2@````,#`0`!`````/___Q!1`0`!`````:>$`Q%1!``!````$1<``!)1
M!``!````$1<```````"@A@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,
M"PL,&1(3#Q0=&A\>'1H<'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T
M,O_;`$,!"0D)#`L,&`T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_``!$(`)L"_P,!(@`"$0$#$0'_
MQ``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#
M!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!
M`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<`
M`0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/>D0."2
M6SN/1B.].\I?5_\`OL_XT1?</^\W\S3Z0#/*7U?_`+[/^-'E+ZO_`-]G_&GT
M4`,\I?5_^^S_`(T>4OJ__?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\
MI?5_^^S_`(T>4OJ__?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_
M^^S_`(T>4OJ__?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_^^S_
M`(T>4OJ__?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_^^S_`(T>
M4OJ__?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_^^S_`(T>4OJ_
M_?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_^^S_`(T>4OJ__?9_
MQI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_^^S_`(T>4OJ__?9_QI]%
M`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_^^S_`(T>4OJ__?9_QI]%`#/*
M7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_^^S_`(T>4OJ__?9_QI]%`#/*7U?_
M`+[/^-'E+ZO_`-]G_&GT4`,\I?5_^^S_`(T>4OJ__?9_QI]%`#/*7U?_`+[/
M^-'E+ZO_`-]G_&GT4`,\I?5_^^S_`(T>4OJ__?9_QI]%`#/*7U?_`+[/^-'E
M+ZO_`-]G_&GT4`,\I?5_^^S_`(T>4OJ__?9_QI]%`#/*7U?_`+[/^-'E+ZO_
M`-]G_&GT4`,\I?5_^^S_`(T>4OJ__?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G
M_&GT4`,\I?5_^^S_`(T>4OJ__?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT
M4`,\I?5_^^S_`(T>4OJ__?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\
MI?5_^^S_`(T>4OJ__?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_
M^^S_`(T>4OJ__?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_^^S_
M`(T>4OJ__?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_^^S_`(T>
M4OJ__?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_^^S_`(T>4OJ_
M_?9_QI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_^^S_`(T>4OJ__?9_
MQI]%`#/*7U?_`+[/^-'E+ZO_`-]G_&GT4`,\I?5_^^S_`(T>4OJ__?9_QI]%
M`#/*7U?_`+[/^-*(PIR"WXL33J*`&1?</^\W\S3Z9%]P_P"\W\S3Z`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"C.**\U^,GC*3PSX<2SL;CRM1OR50C[R1C[S#T/('X
MT`=)%XK35O$$ND:*@N/LC#[=<D_NX0?X1_><^@Z=ZZ&6>.&/?+(D:CJSG`KE
M_AQH46@>!M-A6()<3PK<7#=VD<9.?IG'X5P'Q`U:[O/$MS:/*XM[9@J19XSC
MD_7FLZU54XW.[+\$\95]FG9+5GK,?B#29I?*CU*U9_02"F:WJ%YIMD+^T@6Z
MBAR\\(^^T>.2GJPZX/6OGRO4_AAK%W>07>GW#F2.W56C9CD@'/R_3BL*6)YY
M<K1Z.89+]6I.K"5TM[G:Z)K=AX@TR+4--N%FMY!D$=5/H1V/M6C7@UYJ+?##
MXPM%!(_]BZIMEEM@<(A<XW`?[)'Y$BO>%(901R#TKL/`%HKR_P`:_%BX\*>*
M_P"P[?1/MLAC1U82D%BW8``U1TKXYVK:LMAK^C3Z5N(!D9\A,]V!`('O2`]>
MHKS;Q]\5&\%ZG96D.F)>K=0"97$VWJ2!C@YKGG^.]U87$2ZMX3N+6-^YD(;'
MJ`5&:`/:J*Y'6O'%K8^`&\5Z=&+RWVHR(6VYW,`0?0C-6O`WBAO&/AB+6&M1
M;&21T\L/NQM..M`'245P%I\3+>Y^)L_A#[*JA"T:7/F?>D"[BN,?4?A4_BCX
MB6_AGQAH^ARVPD6^*^;-OQY09MJG&.>:`.XHHK@?B+\2H/`ALX4M4O+NXRQA
M,FS8@_B/!ZGC\#0!WU%<OX#\8Q>-?#JZDD*P2K(T<L(;=L(Z<^XQ744`%%<Y
MXX\3MX0\,3:PMJ+DQNB^67VYR<=:\S7X[ZD;(7O_``B,AM,_ZX2ML_/;B@#V
M^BN2\'>.]/\`&>B37UFCQ3VXQ/;N<E#C(Y[@XZUG?#SXBOXXN=1B;3A:?9-O
M(DW;LDCT]J`.^HKSKQI\6],\+:@-,L[9M3U+=MDAB?`C/8$X//L*SO#WQLL;
M[65TO7=,DT>9\!'E?*Y/0-D`C/K0!ZM145Q<1VUM)<2-MCC0NQ]`!DUPWP^^
M(R>.KK4H19"V%IM*$2;MZDD9Z<=/UH`[ZBN)T_X@0ZA\2;[PG';KMMHR?M&_
M[S@`LN,=LD?A53XB_$B3P+=V$":8+PW:LW,FW;@@>A]:`/0:*\</QB\1XX\"
MW?YO_P#$UU7COQ[)X+T'3]2_L\7#7;A&C:39L^7/I0!W-%>*-\=-1MH([N\\
M(3QVCX(E\U@"#W!*XKT/PAX]T3QG;L=.F*W,8S+;2C$B>_N/<4`=11110`44
M44`%%%%`#(ON'_>;^9I],B^X?]YOYFGT`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%?.
M?[0:R#QCIK-GRS880GIG>V?Z5]&5P7Q5\$GQAX:S:HIU*S)DMR>K#^)/QX_$
M"@#H/!VJQ:UX0TJ^B88DMDW`'[K`88?F#63XM\"1:_,;RUE$%X0`Q;E7`]??
MWKPGX<?$:\\#7[6-VADTJ64>?$P^:$]"R^_J/:OIS2]5LM:T^&_T^X2XMI1E
M)$/!]OK2G!25F;4,14P\_:4W9GEL?PLUEGP]Q:HN?O;B?TQ7HGAOPY:^'+'R
M(1NE?F64CES_`(5MUY5\2_BS;^'(Y=)T9TGU8Y61OX;?(Z^[>WYUG3H0@[HZ
M<5F6(Q4>2H]/(\W^->JP:G\01#:.)&M(5@8K_?R21^&:^D].#C3;82??\I<_
ME7S1\*_!-QXP\3?VKJ"L^FVTIEFE)YEESD+[Y/)KZ@7`&!6QP'SQ\2M0M])^
M.5AJ%T6%O;"WDD*C)"CKQ5#XF>+M.^(FH:99>'-/N)KE'93(T0#2;L87UQQW
MK3^(-K!>_'O3+:YB26"4VRO&XR&'H:]PTOPWHNBEFTS2[2T8\%H8@I/XT`?/
MGQ;M9=)U'PG:W#;Y;32XDD/7+*<'^57O''Q'M/'FDVOAS2M(=;J:9`LMTR*5
M([`GID]\U+\>,?\`"<:(,#'D+Q_VT-;/QN\)1OH%GXAL+>..2T*I<&-0I*-C
M!X]&_G0!:\1^'9?"O[/TVE3R!YXPKR$'(#-*&('L,UI_!^\BT_X2)>3MMB@>
M>1S[`DUCZYXA'B7]GB6^9B9D2."8MUWHZ@_GP?QKG[?51IG[-K1A]LEY=/;J
M/7+Y/Z`T`<?I+7UKXDT?QE<-B&]U5V#9YR&!;/MA_P"=7OB%<7?B'QCK^OP-
MNL=*GBMPX/`P=HQ_P($_C78^,/"#VOP(T5HQ^^T_9=S>O[P'</P++_WS4WAG
MP:;CX!ZIO&;K44:\&>O[LY0?CMS_`,"H`]DTB]34-&LKU6#+/`DF1[@&O#K:
M"'XC_'.\:YC$VFZ>K+MZ@JGRC\V)-7]`\;?V9^S\UQ]HV7D.^P@;OO)^4_@K
M`_A6/\._ACK&J>'EUJV\0W&DO>$C9$IRZ`G!)!'?-`%WX77<O@KXE:KX-O3^
M[N'(B?/&Y1E3_P`"4_F*]ZKYC\?^&-7^'VNZ5KAU:74;B23>+B12"'0@A3R<
M\&OHS0]3CUG0[+4HB-EU"DHQVR,XH`XSXU_\DTO/^NT7_H5>6^'OB0=$^&+Z
M"NA3W#,DJ?:7&81O)Y(QVS7J7QK_`.29WO\`UUB_]"KA?`WQ,\->'OAPFD:B
MLMQ=+YNZV$65<,Q(!/3!S0!N?!;0(],\,:GJ`U&UNI+Q!F.WDW>4`IX;T/-8
MGP)F^SR^)Y\9\N-7Q]-QI/@7:7C3>(M26)H=.EBV(O\`"7R3@?[H./QJ3X!Q
MK->>)(FY5U13]"6H`D^!MC#K6M:]XCO8UENS(H1G&=I<LS$>_`KH_CGHEI=>
M"3JAB1;NSF0K(!@E6.T@GTY_2N.\$ZY%\+/&VMZ)KP>VL;A@T4Q0GH3L;CL0
M3T]*O?%'Q_I_B[2[;PSX8=[^:[G7S"D;`8'(`SC))_E0!N:AXK:W_9]M]0N9
M2;NZLA:*Q/+.<IG\@37G?PQO9O!OC0B_;R8+K2C<9/`*E/,4_D"*Z#X@:>+:
MP\#>``<R#89L'JQ.W/YEZ3X\:%%9S>'Y[2+;NB-EE?1<;1^1-`')^"Y;^S\;
MZ%XHN&80:EJ4D)9L\EL`Y]LO_P".FNP_:!?R]:\/28SM21L#V9:N_$KPZOAK
MX1Z%#:`K+IMS$^_OO8$D_P#?1K"^,6J+J</@W5&X$]IYS8[9*$_UH`[&R^-M
MO<7%O:CPUJ2F1ECW$C`R0,]*J_M"?\BOI7_7V?\`T`UN+\:_!:1*#>7.0HS_
M`*.U8'Q]F2X\'Z--&<I)<[E)]"E`'H7A.V@N_`.C07,,<T36,09)%#`_*.QK
MQ:#3QX*_:`MK'3&V6TTZC9GI'(N2OT']!74:9\9O#>B>"["UC%Q<W]O:I&81
M'M4L`!]X]JP/ASHNL^-OB%_PF>JP,EI'(95?HI<#"HH/)`]?:@#Z$HHHI`%%
M%%`!1110`R+[A_WF_F:?7E'B3Q=K6D^*;VVM;O$$;C;&R`@9`/\`6HX/B=K$
M8Q+!:R^^TC^M<[Q4$VF>K')\1."G&SNK[]SUNBO,(_BK<C'F:7$?]V4C^E7[
M;XI63D"YL)X_>-@W\\4UB:;ZF4LKQ<?L?D>@45R,?Q&\/N/FEN$/HT)_IFI1
M\0O#O_/W)_WX?_"K]M3_`)D8O`XE?\NW]QU-%8MOXMT2ZQY=\@S_`'_E_G6G
M%>VLXS%<1/\`[K@U2E%[,QE2G'XDT3T4F0:,U1F+11FDS0`M%)FEH`**,T9H
M`**,T4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!Y'\3?A
M''KQEUK0PL6I8+2V^/EN#[>C?SKROP+JGBKPSXCEMK#=;K'@WT-X"(HHP1N9
MP?N\=QR>V:^KSBOFWXR^)%U3Q9-HNG0QHL3)'<RHN'N)!T5CW"D\>],"QXW^
M-M_JB2:?X?0V=J04>Z/^LD]T_NC]?I7/^`OAIJGC6Z%W<&2VTO<&DN7!W2\\
MA/4^]<_K_A36?"%S:#6+-(FG7S8P6#JP!Z''\J^K/!FKV>N^$M.O[&!8(7B`
M\E5PL9'!4#T!!H`T-'TBRT+2X-.T^!8;>%0JJHZ^Y/<^]7Z**0%&;1=+N+];
MZ;3[:2[3&V=X@7&.F#UXJ[CC%+13`H7NB:7J,R37NGVMS*@PKRQ*Q4>Q(JS<
M6MO=VS6US#'+`XPT;J&4CT(-344`9Z:%I,=@]@FFVJV<C;G@$2A&/')&,=A4
M;^&]$DM([1]*LVMHV+)$8%VJ3U(&.M:E%`$,]I;W-JUK-#');LNUHG4%2/0C
MTI8[:"&V6VCB1(%78L:J`H7IC'I4M%`&3_PC&A?91;?V19?9P_F"+R%V[L8S
MC'7'>M&WMH;2!(+>)(H8QM1$&%4>@%2T4`5;[3;'4X1#?VD-S$&W!)D#@'UP
M:DM+2VL;9+>T@C@@3[L<:A5'T`J:B@""\L;74+<V]Y;Q7$)()CE0,IQ[&LU?
M"7AQ2"-"T[(Z?Z,G^%;-%`$45M!#"(8H8XX@,!$4!0/H*KV&CZ;I;2-86%M;
M&3[YAC"[OKBKM%`&1KGAC1?$D`BU;3X;H+]UF'S+]".1570?`_ASPU(9=*TN
M&&4\>:?F?\">170T4`4YM)TZXOHKZ:RMY+N+'ES/&"Z?0]13[O3[.^$8N[6&
M<1,'3S4#;6]1GH:LT4`5[NQM=0MS;WEO%<0L03'*@93CV-59_#VC744,5QI=
MG+'`NV)'A4A!Z`8XK2HH`Q?^$0\-_P#0"T[_`,!D_P`*NWFD:=J$$<%Y8V]Q
M%']Q)8PP7MP#TJ[10!D1>%O#\#[XM$T]&]1;)_A6JB+&@1%"J.@`P!3J*`"B
MBBD`4444`%%%%`'AOC;_`)''4?\`?'_H(K`KU77/A\=:U6YU%+\1M,W*-'D#
M''7/M6!<_#+58<FWN+>;V)*UYE2A4YF['V&$S+"JC"#G9I)=>QQ-%=#-X'\1
M0'G3RX]8W5OZU0F\/ZQ;#,VF7:J._E,16#IR6Z.Z&)HS^&:^]&?2TYH9$.'C
M=2.Q4BF=\5)K=/86GJS*<JQ'T.*92T`]2S'?WD9_=W=PG^[*P_K5N#Q#K-NP
M,>IW?_`I2P_(UF#K2U2E);,RE1IR^**?R.FA\>>((@`;I)!_MQ"KL7Q'UE1\
M\5J__`"/ZUQPI:M5JBZG/+`X:6\$=U%\3+P'][I\+#_9<BM*'XFVI`\[3YE/
M^RX->:"G`9JEB:BZF$LJPK^S^+/58OB+H[_>2Y3ZH#_(U;C\=:`YP;MD/^U$
MW^%>0BEJUBZAC+)L.]FSVJ/Q1HDOW=2M_P`6Q_.K*:QITGW+ZW;Z2"O#>].P
M*M8R75&+R2GTDSWE+B&092:-OHP-2Y![BO!%9EY5B#[&KD.JZA!_JKV=/I(:
MI8SNC&62/[,SW"BO&T\3:TG34KC\6S_.K$?B_78S_P`?[-[,BG^E4L9#JC%Y
M/66TE^/^1ZY17F,/CS5TQY@@D^J8_E5Q/B%<C_66,1^CD?TJUBJ9C+*\2ME?
MYGH5%<*OQ"S][3S^$G_UJM1>/[,\26<Z_0@U2Q%-]3)Y?B5]G\CL**YN+QOI
M$GWC,GU3/\JLIXKT9_\`E\`^J,/Z5?M8/J9/"UUO!_<;=%9:>(=)?IJ$`^K8
M_G5A-3L9/N7<#?204U*+ZF;IS6\67**B%Q"P^65#]&%/#J>A'YU5R;,=129H
M!H$+1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`"&O#_``YX,6U^.^I?VI#YJ*)+ZT+C*R%B,$9ZE<GZ&O<:J76G6]W-
M#/(G[^`DQ2J<,A(P<'W'4=Z`./\`B[IMI??#G4Y+@+YEJ@FA<CD,"!@?7.*F
M^%.E7>C?#W3K6]C,4S;I2C=5#,2,_A74WNFV^H>4+M!+'&P<1-RI8'()'?%6
MP,4P%HHHI`%%%%,`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHI`%%%(:`%HIAD5?O$#ZFF)=6[R^4LT9?'W0X)
M_*@=F/B^X?\`>;^9I],B^X?]YOYFGT"#`I,#TI:*`(W@BD&'B1O]Y0:I3Z%I
M-R")=.MFS_TS%:-%)Q3W*C.4?A=CF)_`7A^<D_8VC_ZYR%:I3?#31G!\J:[C
M/^^"/U%=GBEQ4.C3>Z.B.-Q,=IL\VN?A<X.;;4EQZ21_X&J$GPUU=`=DUM)]
M&(_F*]8HK-X6F^ATQS?%+>5_DCQB?P/X@@!/V,2`?\\W!_K6;+HFJP$B73KI
M?^V1->\8%&T5#P<>C-XYW67Q13^\^?&AECXDC=3_`+2XI*^@GAC<8=%8>A&:
MIRZ'I<YS)I]LQ]?*%9O!/HS>.>+[4/Q/"Q2U[/+X1T*8$'3HA[KD5F3_``\T
M>0_NVN(?]U\_SJ'A)K8WCG5!_$FCRSO3A7HC_#6U/^KU&8?[T8/^%4KCX<7:
M?\>U]%)_OJ5_QJ'AJG8V6:867VOP9Q0Z4X5T4G@77(\XAB<?[,@_K5:3PIK<
M62;"0C_9(/\`6H=*:W1LL70EM-?>8_:G"K,NFWUOQ-9SI]8S5?!!P00:BS6Y
MJI1EL[BCK3N]-'6G=Z5Q,<*=313J`%%/'6F"GCK3)'"G"D%*#3)8]68'@D?0
MU*MQ,O2:0?1C4(Z4X4TR6D]RXFH7D?W;N<?\#-6HM=U2/I>RX]SFLRGBJ4Y+
MJ9.E3>\5]QM)XGU9?^7D-]4%3+XMU0#EHC]8ZP`:<#5*K-=3)X:B_LHZ)/%V
MH_Q)`?\`@)']:LQ^,9^/,M4/^ZQ%<N#3^E7[>IW,G@J#^R=:OC!/XK1_P<5,
M/%ML>L$H_$5Q].!XJUB)F;P%#L=D/%-F>J2C\*D7Q+8-U:0?5:XL&G`TUB)F
M;R^CTN=PNOZ>W_+?'U4U*NLZ>W2[C_$UP5&[%5]9D2\MI]V>@KJ5DW2[A_[[
M%/%[;-TN(C]'%><DY'6FFCZR^Q/]F1Z2/2Q<1-TE0_\``A3O,4]''YUYABF[
MF7H2/H:?UKR%_9G:7X'J61ZBES7EOVB=?NS2#Z.:7[?>*.+J8?\``S1];787
M]E2_F_`]1S17EW]J7XZ7D_\`WV:4:QJ0Z7TW_?5/ZW'L+^RJG22/4*,UY>-?
MU53Q?2_G3QXDU<?\OKGZ@4?6X=A?V55[H]-S17F8\4ZP/^7O/_`!3QXOU=>L
MR'ZH*?UN`GE=?R/2<T5YR/&NJJ.1`?\`@-/'CO4AUAMS]0?\:?UJF3_9>([+
M[ST.EKSW_A/K\?\`+I;'_OK_`!I?^%@7W_/G;_FW^-'UFGW#^S,1V_$]!HKS
MT_$*]'_+E!_WT:/^%B7?_/A`?^!FCZS3[B_LS$]OQ1Z%17GO_"QKK_H'P_\`
M?P_X4?\`"Q[G_H'0_P#?T_X4_K-+N']F8G^7\4>A45YY_P`+(N?^@9%_W^/^
M%'_"RKC_`*!D?_?X_P"%'UFGW#^S,5_+^*_S/0Z*\[_X67/_`-`N/_O\?\*/
M^%ES_P#0+C_[_'_"CZS2[C_LO%?R_BO\ST2BO.O^%F3_`/0+C_[_`)_PI/\`
MA9MS_P!`J+_O^?\`XFCZS2[A_9>*_E_%?YGHU%>;GXG7(_YA<7_?X_X4G_"S
MKK_H%P_]_3_A1]9I=Q_V5BOY?Q7^9Z317FA^)]YVTR#_`+^G_"F_\+/O?^@;
M;_\`?;4?6:7</[)Q7\OXH]-HKS`_$_4.VGVW_?34T_$_4NUA:?FW^-+ZU2[E
M+*,5V_%'J-)FO*W^)VJG[MI:#\&_QJ"3XD:TPX2U7Z(3_6CZU3&LGQ3Z+[SU
MO-&?>O''^(.OOTGB7Z1BJ[>.?$+?\OY'T1?\*EXN!HLDQ+W:/:Z,UX:_C#Q`
M_!U28?3`_I4#>*-=;KJMS_WW2^N1[&BR*M_,OQ/><T$@=37@#:_K#]=3N_\`
MOZ:ADU7491\]_=-]9F_QJ7C%T1:R&IUFON/H(RQKUD4?4U$]_9QCY[J%?K(!
M7SP\LDAR\CM_O,33<4GC.R-%D'>I^'_!/H"3Q!H\7W]4M!_VV6J4WC/P]`"6
MU2%L=DRW\A7AE(>*EXR71&L<AI=9O\#V2;XC^'X_NRSR?[L1_K523XI:0H^2
MVNG_`.`@?UKR4TE2\749M'),,M[OYGI\WQ7M@#Y.ERL?]N4#^E95S\4]6<_Z
M/9VL0_V\N?YBN%[45#Q%1]3>.4X2/V+_`#9UDGQ(\1R`XFMX_P#<A']2:S;K
MQ?K]V-LNIS@>B';_`"K%I#4.K-[LZ88/#P^&"^XGEO[R8DRW<[Y_O2$UO_#X
MY\<:>3R<2?\`HMJYBNG^'W_([Z?])/\`T6U%-MU(^J%BXQ6&J67V7^1[;%]P
M_P"\W\S3Z9%]P_[S?S-/KV#X(****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`$Q1BEHH`3%&*6B@!"H/45"]I;R_P"L@B;_`'D!J>BBPTVMC/ET/2IOOZ?;
M'W$8'\JI2^$-%D_Y<PO^ZQ']:W:*EPB]T:1KU8[2?WG,R>!=(?[OG)]'JE/\
M/H"?W%[(O^^H-=G14.A3?0UCC<1'[;.`;X?W:_<OH6^J$57D\$:I']QH)/HQ
M'\Q7H])BH>%IFT<SQ"ZW^1Y9+X9UB(X-D[>ZD&J[:1J,?W[*<?\``#7K>*,5
M#P<>C-5FU7K%'CSP31_?AD7ZJ130>U>PL@;JH/U%02:;9S?ZVUA?ZH*EX/LS
M6.;K[4/Q/)QS3A7IC^'M*?K8Q#Z#'\J@?PII+CB!D/\`LN:AX6?1FBS2D]TS
MSP4\5V[>#+$GY99E_$'^E0/X*BQ\EW(/JHI/#5$6LPH/K^!R(-.!KHY/!ER.
M8[F-O]X$57;PGJB]!"WT?_ZU2Z,UT-%BZ$OM&.#3P:T6\-:J@)-N#CTD6JSZ
M9?0_?M)?P7-)TY+H4JU)[27WD`-+F@PRH?FB=?JIIIR.H-3L7=#LT9INZC/I
M0.PI-)FD)XIN?2@!2:83033:3&D!-,)I2::>:10AIII33#2*0AIN:6D-!2&D
MTT^M*:0FI&AIZ4RGFF&@H0]Z::4FD/2D4AM--*:;0,2D-*>E-)XH*$IAIYZ4
MR@8AIM./6FT%"'K33UI>])0,;2&G4TT#&FDI324#04PTX]:::"D-HI1UI#0,
M0G-%!HH&)2&E-(:`$HHHH&A****8!2&EI#2&(:2E-)0`4444P"D)S2GI3:0P
MKI_A]_R.^G_23_T6U<Q73_#[_D=]/^DG_HMJNE_$CZHY\9_NU3_"_P`CVV+[
MA_WF_F:?3(ON'_>;^9I]>R?`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M"$4F!3J*`&E0>HS3&@B/6-3]5%2T4`G;8IR:992_?M8C_P`!JL_AW2WZVP'^
MZQ%:M%2X1>Z+56:VDS#;PKIIZ"5?H]02>$+,C]W-,OU(/]*Z.BI=*#Z&BQ59
M?:9R;^#1_#>'\4_^O4+>#9\?+=1GZJ17945+P]/L:+'5U]HX23P?J"\K)"WX
MD53D\-:LF<6N_P#W6%>CT5+PL#59E678\Q;0M67K83?@`?ZU7DTR_C^_9SK]
M4->K45+PD>C-5FM3K%'CSQR1G#QLI]Q41->QO&CC#*K#W%0/I]F_WK6%OJ@J
M/J?9FJS9=8?B>1=:::]9?1=-?[UC!_WP*KOX9T>3K9(/ID5+P<NYHLVI]8L\
ML)IIKTJ7P5I$GW4EC_W9#_6JK>`;`GY;JY4>^#_2H^JU#:.:X?K?[CSTTTUW
MS_#Z`_=OY!]8P?ZU5D^'L@_U>H*?]Y"/ZU+PU3L:K,L,_M?@<2:;76OX`U('
MY;FW8?4C^E0-X$U?L;=O^!__`%JAT*G8U6.P[^VCESTIIKHY/!6MITMXV_W9
M!5.7POK4?6PD/^[@U+IS70UCBJ#VFOO,<]*;5Z72-2C^]I]T/^V3'^E5VL[I
M/O6LZ_6-A_2IY7V-5.+V:(#334ABD7K&X^JFHV&*3-4QII*4FFT#04T]Z4]*
M::!C30:.M%!0VD-.:FT`A!UI#1104)1124#`\4W.:=VIM`!1124#04444P"D
M-+32<TA@:2E-)0`4444P`]*;3CTIM(85T_P^_P"1WT_Z2?\`HMJYBNG^'W_(
M[Z?])/\`T6U72_B1]4<^,_W:I_A?Y'ML7W#_`+S?S-/ID7W#_O-_,T^O9/@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`,48HHH`*,444`%%%%`!1110`C(K##*"
M/0U5DTRPF_UEG`_UC!JW119#3:V,F3PUHLGWM,MOP3'\JKOX.T%^NGH/H3_C
M6]1BH=.'8U6(K+:3^]G--X%T%^MJP^DA%5Y/AYH;_=6=/I(:ZW%&*7L:;Z%K
M&XA;3?WG#R_#333_`*N[N4_(_P!*J2?#!#_J]4<?[T0/]:]#I,5+P])]#6.9
M8J.TSS5OA?<_PZI$?K$1_6H6^&&H_P`.H6I^H8?TKU'%&*GZK3[&BS;%K[7X
M(\GD^&>L)]VXM'^C,/Z54D^'FOI]V&%_]V4?UKV/%&*7U2F:+.<4NWW'BC>!
M/$2_\N&?I(O^-0OX+\0+_P`PV4_0@_UKW#%&*7U2'<T6>8CJD>$/X4UY.NEW
M/X+FJ\F@:Q$/GTR['_;(FO?\48J7@X]RUGU7K!'SM)97</\`K+6=/]Z,BJ[?
M*?FX^O%?2!C0]5!^HIC6L#?>AC/U04OJ2[FBS]]8?C_P#YPW*?XA^=+FOHIM
M.LF^]:6Y^L0_PJ%M$TI_O:=:-]85_P`*GZF^YI_;T.L']Y\]FDKWU_"^AR?>
MTJU_",#^559/`_AR7KID8_W68?UI/!S[FD<^H]8L\+-)7M;_``Y\./TMI5_W
M9FJN_P`,M`;[OVI?I+_]:I^J3-5GF&?1_<O\SQS-+7KC_"[1C]V>Z7_@0/\`
M2H6^%>FG[M_<C\%-+ZK4*6=87N_N/*3TIM>HO\*+;'R:I,/K&#5:3X3O_P`L
M]6'_``*'_P"O4O#5>QHLWP;^U^#/-ZZ?X??\COI_TD_]%M6M)\*M37_5W]LW
M^\K"M+PKX#U71?$MK?W,MJT$0?=L8Y.4('&/>JIT*BFFUU(Q.8X6="<8SU:?
M?L>BQ?</^\W\S3Z0`*,#US2UZA\<%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
A`!1110`4444`%%%%`!1110`48%%%`!1110`4444`?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
